Adding TACE to Lenvatinib Improves Survival in Liver Cancer
Transarterial chemoembolization (TACE) added onto lenvatinib is a new first-line option for patients with advanced liver cancer, say LAUNCH trialists.
Medscape Medical News
source https://www.medscape.com/viewarticle/967184?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/967184?src=rss
Comments
Post a Comment